Johnson & Johnson Q2 2026 results and raises 2026 outlook
- Q2 reported sales $25,310 million, up 6.6% year‑over‑year.
- Adjusted net earnings $7,081 million (up 5.7%); adjusted diluted EPS $2.90 (up 4.7%); GAAP net earnings $5,534 million.
- Raised full‑year estimated reported sales to $100.8–$101.4 billion (midpoint $101.1B) and adjusted EPS midpoint to $11.68.
- Announced >$1 billion investment in U.S. vision manufacturing and agreement to acquire Firefly Bio to expand oncology pipeline.
Quarter results
Reported Q2 sales were $25,310 million, a 6.6% increase versus Q2 2025; GAAP net earnings were $5,534 million (flat year‑over‑year). On a non‑GAAP basis, adjusted net earnings rose to $7,081 million (up 5.7%) and adjusted diluted EPS to $2.90 (up 4.7%). Free cash flow for the second‑quarter year‑to‑date is estimated at approximately $8,700 million versus $6,214 million prior year.
Drivers by segment and region
Innovative Medicine drove growth (6.8% operational), led by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in oncology, TREMFYA in immunology, and SPRAVATO and CAPLYTA in neuroscience; STELARA and REMICADE weighed on immunology (STELARA ~760 basis‑point headwind). MedTech grew 3.6% operationally, supported by wound closure, biosurgery, electrophysiology, Shockwave, contact lenses and trauma.
Guidance
Management raised its full‑year outlook: estimated reported sales of $100.8–$101.4 billion (midpoint $101.1B) and adjusted EPS range implying a midpoint of $11.68. Adjusted operational sales growth guidance was raised to a 6.2–6.8% range (midpoint 6.5%).
Other corporate and regulatory items
Notable items include planned acquisition of Firefly Bio, a >$1 billion investment to boost U.S. vision manufacturing in Jacksonville, and several regulatory milestones and data readouts including FDA approvals and CHMP recommendation activity for pipeline assets such as TECVAYLI and IMAAVY.
Source: J&J